Aimovig (erenumab-aooe) / Amgen, Novartis 
Welcome,         Profile    Billing    Logout  
 12 Diseases   17 Trials   17 Trials   2487 News 


«12345678910111213...2425»
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Comprehensive assessment of erenumab efficacy in patients with high frequency episodic migraine with at least one previously failed preventive treatment: The EMBRACE study () -  Jun 18, 2024 - Abstract #AHS2024AHS_340;    
    P4
    In this trial, participants treated with erenumab reported spending significantly fewer hours with a headache of moderate or severe pain intensity every month while also experiencing significantly lower impact of migraine on usual activities and measures of physical, social and emotional functioning. In addition, the EMBRACE trial provided confirmatory evidence to support that treatment with erenumab produces an enduring impact on residual migraine attacks with remaining events being less painful overall as measured by the significant reduction in the average peak pain intensity per attack and the average time spent with a moderate-to-severe headache on remaining recorded attacks as compared to placebo.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Biomarker, Clinical, Journal:  Hypersensitivity to CGRP as a predictive biomarker of migraine prevention with erenumab. (Pubmed Central) -  Jun 11, 2024   
    P4
    Our findings suggest that the CGRP-provocation model cannot be used to predict erenumab's effectiveness. It remains uncertain whether this finding extends to other monoclonal antibodies targeting the CGRP ligand or to gepants.Trial Registration: The study was registered at ClinicalTrials.gov (NCT04592952).
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Clinical, Journal:  Induction of cGMP-mediated migraine attacks is independent of CGRP receptor activation. (Pubmed Central) -  Jun 8, 2024   
    P=N/A
    It remains uncertain whether this finding extends to other monoclonal antibodies targeting the CGRP ligand or to gepants.Trial Registration: The study was registered at ClinicalTrials.gov (NCT04592952). These findings provide evidence that migraine induction via the cGMP pathway can occur even under CGRP receptor blockade.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial completion:  MicroRNA Profile and Erenumab Treatment (clinicaltrials.gov) -  May 28, 2024   
    P=N/A,  N=40, Completed, 
    These findings provide evidence that migraine induction via the cGMP pathway can occur even under CGRP receptor blockade. Active, not recruiting --> Completed
  • ||||||||||  Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
    Journal:  Safety considerations in the treatment with anti-CGRP(R) monoclonal antibodies in patients with migraine. (Pubmed Central) -  May 14, 2024   
    We observed CV events in 1.6% of patients with 1.5-year follow-up of anti-CGRP(R)-mAbs treatment. We advise awareness regarding CV events in patients with migraine undergoing CGRP-targeted treatment, not as a confirmation of increased risk but as a proactive measure to address potential multifactorial influences.
  • ||||||||||  Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva
    Journal:  Treatment Outcome After Switching From Galcanezumab to Fremanezumab in Patients With Migraine. (Pubmed Central) -  May 7, 2024   
    The treatment response to fremanezumab seems to be independent of the prior treatment response to galcanezumab. Our findings suggest that switching to another anti-CGRP mAb can be considered when a particular anti-CGRP mAb is ineffective or intolerable.
  • ||||||||||  PK/PD data, Review, Journal:  Anti-calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Clinical Pharmacokinetics. (Pubmed Central) -  Apr 26, 2024   
    Since the elimination processes do not have a large capacity, the half-life is about 2 weeks for erenumab and about 4 weeks for other monoclonal antibodies. Variability in the pharmacokinetics of these monoclonal antibodies is small in different subpopulations, and body weight is the only parameter to consider when choosing the dose of these drugs.
  • ||||||||||  Review, Journal:  Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in Migraine: Focus on Drug Interactions. (Pubmed Central) -  Apr 26, 2024   
    However, monoclonal antibodies may worsen diseases with already weakened CGRP neurotransmission, Raynaud phenomenon and constipation. Monoclonal antibodies used for prevention of migraine do not engage in significant pharmacokinetic interactions with other drugs; however, they do engage in pharmacodynamic interactions with other anti-migraine drugs, additively augmenting their prophylactic action, but also increasing frequency and severity of adverse reactions, which are a consequence of the CGRP neurotransmission interruption.
  • ||||||||||  Clinical, Review, Journal:  Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. (Pubmed Central) -  Apr 23, 2024   
    Monoclonal antibodies used for prevention of migraine do not engage in significant pharmacokinetic interactions with other drugs; however, they do engage in pharmacodynamic interactions with other anti-migraine drugs, additively augmenting their prophylactic action, but also increasing frequency and severity of adverse reactions, which are a consequence of the CGRP neurotransmission interruption. The CGRP-targeting therapies should be considered as a first-line approach for migraine prevention along with previous first-line treatments without a requirement for prior failure of other classes of migraine preventive treatment.
  • ||||||||||  Journal:  Preventive Treatment of Migraine. (Pubmed Central) -  Apr 7, 2024   
    Six drugs targeting CGRP (four monoclonal antibodies and two gepants) are now available for the preventive treatment of episodic migraine in adults. The efficacy of CGRP-targeted medications in the acute and preventive treatment of migraine, together with good safety and tolerability, has led to the emergence of new approaches to preventive treatment.
  • ||||||||||  Enrollment open:  Migraine Medication Effects on Urinary Symptoms (clinicaltrials.gov) -  Mar 29, 2024   
    P=N/A,  N=200, Enrolling by invitation, 
    The efficacy of CGRP-targeted medications in the acute and preventive treatment of migraine, together with good safety and tolerability, has led to the emergence of new approaches to preventive treatment. Not yet recruiting --> Enrolling by invitation
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial completion:  AMG 334 20160172 Pediatric Migraine PK Study. (clinicaltrials.gov) -  Mar 27, 2024   
    P1,  N=53, Completed, 
    Not yet recruiting --> Enrolling by invitation Terminated --> Completed
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial completion date, Trial primary completion date, Real-world evidence, Real-world:  Migraine Survey in Gulf Region (clinicaltrials.gov) -  Mar 26, 2024   
    P=N/A,  N=200, Not yet recruiting, 
    Terminated --> Completed Trial completion date: Oct 2024 --> Jan 2025 | Trial primary completion date: Oct 2024 --> Jan 2025
  • ||||||||||  Vyepti (eptinezumab-jjmr) / Teva, Lundbeck, Aimovig (erenumab-aooe) / Amgen, Novartis
    Cost-Utility Analysis of Eptinezumab Versus Erenumab for Episodic Migraine Headaches Patients in the United States () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2204;    
    The safety profile of erenumab in children and adolescents is consistent with that in adults. Eptinezumab was cost-effective at a WTP threshold that was greater than $19,753 per additional QALY gained; however, the probability of cost-effectiveness was slightly higher than the indifference level of 50%.
  • ||||||||||  Determinants of Innovative Drugs' Adoption: Evidence from Lithuania () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_402;    
    Institutional factors and price play a critical role in defining the speed of innovation diffusion in healthcare. Also, data suggests potential geographically defined inequality of Lithuanian doctors
  • ||||||||||  Vyepti (eptinezumab-jjmr) / Teva, Lundbeck
    Real-world Effectiveness of Intravenous Eptinezumab in Patients with Chronic Migraine and Previous Subcutaneous Preventive Migraine Treatment (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3916;    
    All patients (94/94) self-reported prior preventive therapy with 89% (84/94) reporting prior subcutaneous anti-CGRP mAb use (i.e., fremanezumab, galcanezumab, or erenumab). This real-world, patient survey showed that patients with prior exposure to subcutaneous anti-CGRP mAbs had high overall satisfaction with the effectiveness of eptinezumab treatment regardless of the number and type of previous therapies used.
  • ||||||||||  The Safety and Efficacy of Dual Calcitonin Gene-related Peptide Therapies for Migraine Treatment (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3206;    
    The observed reduction in headache severity and frequency suggests a dual blockade is beneficial for migraine symptom control in selected patients. Safety regarding this treatment option is also supported by these findings; specifically, the small molecule antagonists appear to be the safest option to include in dual regimens.
  • ||||||||||  Qulipta (atogepant) / AbbVie
    Benefit-Risk Assessment Based on Number Needed to Treat and Number Needed to Harm: Atogepant vs Calcitonin Gene (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_3006;    
    The base-case analysis included data from core studies of atogepant 60 mg, erenumab 70 mg and 140 mg, galcanezumab 120 mg, eptinezumab 100 mg and 300 mg, and fremanezumab 225 mg and 675 mg. Atogepant demonstrated a favorable benefit-risk profile, with NNT and NNH values comparable with those of CGRP mAbs across all scenarios.
  • ||||||||||  Qulipta (atogepant) / AbbVie
    Real-world Switching Rates of Atogepant Are Lower than CGRP Monoclonal Antibodies (mAbs) in Patients with Migraine Using Claims Database (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_2727;    
    Patients were excluded if they had ?1 claim for atogepant, rimegepant, BOTOX for migraine, or a CGRP mAb in the 12 months preceding the index date...At 12 months follow-up, 13.4% of atogepant users and 21.1% of CGRP mAb users (23.1% eptinezumab, 26.5% erenumab, 19.6% fremanezumab, 18.4% galcanezumab) initiated a different branded preventive. Compared with atogepant users, CGRP mAb users were significantly more likely to switch to another branded preventive treatment within 1 year of treatment initiation.
  • ||||||||||  Reasons for Discontinuation of Medical Management in Refractory Idiopathic Intracranial Hypertension (Colorado Convention Center | Exhibit Hall B-E) -  Mar 8, 2024 - Abstract #AAN2024AAN_2471;    
    Our study results suggest that medical management available for IIH may not be suitable for all patients, and many may discontinue the medication due to adverse effects or no improvement in symptoms. IIH patients refractory to medical management are a challenging sub-group requiring invasive and surgical diagnostic and treatment modalities.
  • ||||||||||  Review, Journal, HEOR:  Anti-CGRP mAbs for the Preventive Treatment of Migraine: An Overview Review and a Cost Saving Analysis in the Global Scenario. (Pubmed Central) -  Mar 7, 2024   
    In fact, all extracted studies showed a protective risk factor exposure in monthly migraine days reduction for all the anti-CGRP mAbs, whereas the cost analysis showed that using eptinezumab, in a quarter there is a cost saving of at least $425 per patient, compared with the other anti-CGRP mAbs. With equal efficacy and equal safety, anti-CGRP mAbs should be prescribed also regard to the cost established at the negotiation, making sure to guarantee the best treatment to the patients, but at the same time impacting as little as possible to the healthcare services resources.
  • ||||||||||  Aimovig (erenumab-aooe) / Amgen, Novartis
    Journal, Real-world evidence, Real-world effectiveness, Real-world:  Real-world effectiveness of erenumab in Japanese patients with migraine. (Pubmed Central) -  Feb 29, 2024   
    Erenumab was effective in migraine patients. At least 4-6 months may be preferable for efficacy evaluation in patients switching to erenumab from other CGRP mAbs.
  • ||||||||||  Retrospective data, Journal:  Effectiveness of Switching CGRP Monoclonal Antibodies in Non-Responder Patients in the UAE: A Retrospective Study. (Pubmed Central) -  Feb 23, 2024   
    Fremanezumab was not included due to unavailability in the UAE...The safety of switching between CGRP classes was well observed, as any adverse events presented before the class switch did not lead to the discontinuation of treatment following the later switch. The findings of this study suggest that switching between different classes of CGRP mAbs is a potentially safe and clinically viable practice that may have some applications for those experiencing side effects on their current CGRP mAb or those witnessing suboptimal response.
  • ||||||||||  Ajovy (fremanezumab-vfrm) / Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
    Trial completion date, Trial primary completion date:  Effectiveness of a Health Education Programme for Prevention of Chronic Migraine: A Randomized Clinical Trial (clinicaltrials.gov) -  Feb 23, 2024   
    P=N/A,  N=182, Recruiting, 
    The findings of this study suggest that switching between different classes of CGRP mAbs is a potentially safe and clinically viable practice that may have some applications for those experiencing side effects on their current CGRP mAb or those witnessing suboptimal response. Trial completion date: Jan 2024 --> Jul 2024 | Trial primary completion date: Dec 2023 --> Apr 2024